Madrs Depression Score Calculator

The MADRS is a clinician-rated severity measure, not a diagnostic checklist. Ten items are each rated 0 to 6 for a total of 0 to 60: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts. The unusual 7-point scaling is the design feature that gives the instrument its sensitivity to change. Only the even anchors 0, 2, 4 and 6 carry written descriptions; the rater assigns 1, 3 or 5 when the patient sits between two anchors. That fine-grained resolution lets a modest improvement register as a score shift, which is why regulators and trial sponsors adopted it as a primary endpoint for antidepressant studies. Commonly cited bands are 0 to 6 for no depression, 7 to 19 mild, 20 to 34 moderate and 35 or above severe. In trials, response is defined as at least a 50 percent fall from baseline and remission is usually set at a total of 10 or below, a threshold examined by Hawley and colleagues in 2002. Item 10 on suicidal thoughts is read independently of the total, since a rating of 4 or more describes explicit plans and demands immediate safety assessment even when the sum is low. Limitations follow from the deliberately narrow item set: the scale contains only one somatic-vegetative pair, so it will not detect atypical features such as hypersomnia or increased appetite, it omits psychomotor agitation and retardation as distinct items, and reliable rating depends on trained interviewers achieving inter-rater agreement.

Stuart Montgomery and Marie Asberg constructed the scale from the 65-item Comprehensive Psychopathological Rating Scale, published in 1978 by the Asberg group at the Karolinska Institute in Stockholm. Rather than selecting items by clinical consensus, they treated sensitivity to change as the selection criterion: they rated British and Swedish patients before and after antidepressant treatment and kept the ten CPRS items whose scores moved most consistently with clinical improvement. The result appeared in the British Journal of Psychiatry in 1979 under the title A new depression scale designed to be sensitive to change, and the cross-national derivation was intentional, intended to produce a measure that behaved similarly in different clinical cultures. The design brief was a direct response to the Hamilton Depression Rating Scale, which Max Hamilton had published in 1960. The Hamilton scale predates modern antidepressant trials, weights somatic and anxiety symptoms heavily, and uses inconsistent item ranges, so patients with physical illness can accumulate points without mood pathology and small improvements are hard to detect. The MADRS traded breadth for responsiveness. It became a standard primary outcome in registration trials for SSRIs, SNRIs and later agents including esketamine, and it is frequently preferred in geriatric and medically ill populations for the same reason it was built. A validated patient self-report version, the MADRS-S, followed, and structured interview guides such as SIGMA were developed to improve rating reliability.